|
Metaproterenol Sulfate Oral Solution
» Metaproterenol Sulfate Oral Solution contains not less than 90.0 percent and not more than 110.0 percent of the labeled amount of metaproterenol sulfate [(C11H17NO3)2·H2SO4].
Packaging and storage
Preserve in tight, light-resistant containers.
Identification
A:
Transfer a portion of Oral Solution, equivalent to about 10 mg of metaproterenol sulfate, to a separator, and extract with four 30-mL portions of ether, discarding the ether extracts. Apply 10 µL of the extracted portion of Oral Solution to the lower right corner of a suitable thin-layer chromatographic plate (see Chromatography
B:
The retention time of the major peak for metaproterenol in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
pH
Assay
Mobile phase
Mix 10 mL of formic acid and water to make 1000 mL of solution. Filter and degas this solution before use. Make adjustments if necessary (see System Suitability under Chromatography
Standard preparation
Dissolve an accurately weighed quantity of USP Metaproterenol Sulfate RS in water to obtain a solution having a known concentration of about 0.2 mg per mL.
Assay preparation
Transfer an accurately measured volume of Oral Solution, equivalent to about 20 mg of metaproterenol sulfate, to a 100-mL volumetric flask, dilute with water to volume, and mix.
Chromatographic system (see Chromatography
Procedure
Separately inject equal volumes (about 100 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of metaproterenol sulfate [(C11H17NO3)2·H2SO4] in each mL of the Oral Solution taken by the formula:
100(C / V)(rU / rS)
in which C is the concentration, in mg per mL, of USP Metaproterenol Sulfate RS in the Standard preparation; V is the volume, in mL, of Oral Solution taken; and rU and rS are the peak responses from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information
Please check for your question in the FAQs before contacting USP.
USP35NF30 Page 3827
Pharmacopeial Forum: Volume No. 28(2) Page 325
|